The founder and CEO of T3D Therapeutics, Inc., spoke about T3D’s desire to go against the grain and trend in the therapeutic development for mild to moderate Alzheimer disease.
“We feel that by reestablishing metabolic homeostasis, you can effectively treat mild to moderate Alzheimer.”
John Didsbury, PhD, Founder and CEO of T3D Therapeutics, Inc., spoke with NeurologyLive at the 2018 Alzheimer Association International Conference in Chicago, Illinois, about T3D’s desire to go against the grain and trend in the therapeutic development for mild to moderate Alzheimer disease.
Didsbury detailed that while much of the medical community has given up—or at least determined it highly unlikely to be successful—on developing treatments for patients in the later stages of the disease pathology, T3D is determined to develop a drug for them, hoping to reestablish an equilibrium in the brain’s glucose metabolism. The company’s current investigative therapy, T3D-959, is somewhat of an embodiment of that sentiment.
The dual peroxisome proliferator-activated receptor (PPAR) delta/gamma agonist with 15-fold higher PPAR delta potency, was studied in 36 patients with mild-to-moderate Alzheimer disease, with data presented at the conference. Didsbury said that thus far, the therapy has shown signs of efficacy, and ultimately, seeks to address a dysfunction in glucose and lipid metabolism in the brain.